PharmaDrug Inc. Advances Pharmaceutical Innovation with Strategic Acquisition of SecureDose Synthetics

NEW YORK-PharmaDrug Inc., a specialty pharmaceutical company, has recently provided a comprehensive update from CEO Robert Steen on their strategic acquisition of SecureDose Synthetics Inc. This move marks a significant step in PharmaDrug’s ongoing efforts to research, develop, and commercialize controlled substances and natural medicines, including psychedelics and previously approved drugs.

SecureDose Synthetics, a private pharmaceutical R&D company, has established a reputation for developing synthetic formulations of existing drugs, with a particular focus on the psychedelic sector. The acquisition aligns with PharmaDrug’s vision to spearhead the third wave of drug policy reform through the development of synthetic formulations.

Under the guidance of CEO Robert Steen, who brings extensive experience in substance abuse clinics, PharmaDrug is addressing critical issues like fentanyl contamination in street drugs. Steen emphasized the company’s stance against drug abuse and its commitment to rehabilitation, while recognizing the complexity of the issue and the need for a multi-dimensional approach to harm reduction.

The integration of SecureDose’s expertise in synthetic formulations into PharmaDrug’s operations is expected to yield significant advancements. The company aims to create biosynthetic versions of substances for safe, scalable, and economically viable production in pharmaceutical-grade facilities. This approach promises a verified manufacturing process, regulated distribution, and the use of locally sourced, legal inputs.

In addition to its R&D efforts, PharmaDrug has initiated collaboration with a regulated university-affiliated lab to further its research activities, potentially leading to the development of novel formulations and valuable intellectual property. Within the next few months, PharmaDrug anticipates announcing its focus drugs and expects to commission its first test batch in the upcoming quarters.

In a strategic move to align interests with external consultants, PharmaDrug has granted 1.1 million stock options exercisable at $0.05 per share, vesting immediately. This decision underscores PharmaDrug’s commitment to fostering innovation through incentivized collaboration.